Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-world study to evaluate the clinical experience and safety of Tenofovir Alafenamide for the Treatment of Hepatitis B in patients from TRIO HBV Registry

Next Previous
Trial Profile

A Real-world study to evaluate the clinical experience and safety of Tenofovir Alafenamide for the Treatment of Hepatitis B in patients from TRIO HBV Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 29 Aug 2020 Results assessing variables associated with TAF adoption from approval 2016 to 2018 presented at The International Liver Congress 2020
  • 29 Aug 2020 Results assessing virologic suppression rates, eGFR, fibrosis, and ALT at 48+ weeks of TAF therapy (n=270; as of Jan 2019) presented at The International Liver Congress 2020.
  • 23 May 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top